Oppenheimer lifts target to USD 60.00 for Pulse Biosciences stock

Published on 10/17/2026 at 20:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pulse Biosciences stock reports on November 5, 2026. It closed at USD 44.43 on Nasdaq October 16, 2026, down 2.54 percent versus its prior close.

Analyst target and valuation

On October 13, 2026, Oppenheimer raised its Pulse Biosciences target from USD 35.00 to USD 60.00.
Pulse Biosciences has its next earnings date scheduled for November 5, 2026.
Pulse Biosciences stock closed at USD 44.43 on Nasdaq on October 16, 2026, down 2.54 percent versus the prior close.
The company had a USD 3.2 billion market capitalization and a negative P/E of -37.97 on October 16, 2026.

PLSE, US74587B1017, Illustration mit AI erstellt.

Pulse Biosciences (ISIN US74587B1017) drew a higher USD 60.00 price target from Oppenheimer on October 13, 2026, up from USD 35.00, according to Investing.com. The target stood 35.63 percent above the Nasdaq closing price of USD 44.43 on October 16, 2026. Pulse Biosciences closed at USD 44.43 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.54 percent versus its prior close.

Earnings date comes into view

Pulse Biosciences is scheduled to report earnings on November 5, 2026, according to Yahoo Finance. The date gives the stock a defined near-term event, while the latest public investor-relations page describes the company as a bioelectric medicine business built around its CellFX System and Nano-Pulse Stimulation technology, according to Pulse Biosciences.

Price sits below the yearly high

The October 16, 2026 Nasdaq close was USD 14.47 below the 52-week high of USD 58.90 and USD 31.87 above the low of USD 12.56. The latest reported volume was 327,405 shares, compared with an average volume of 519,460 shares.

Valuation and company scale

Pulse Biosciences had a market capitalization of USD 3.2 billion and a P/E of -37.97 on October 16, 2026. Its profile lists 116 full-time employees and classifies the business in Healthcare and Medical Instruments and Supplies.

Comparison with peers

Pulse Biosciences (Nasdaq, USD): minus 2.54 percent, P/E -37.97, market capitalization USD 3.2 billion.

InMode (Nasdaq, USD): minus 1.12 percent, P/E 11.51, market capitalization USD 814.8 million.

IRIDEX (Nasdaq, USD): minus 1.20 percent, P/E -4.00, market capitalization USD 14.3 million.

What the next report may clarify

The November 5, 2026 earnings date is the next calendar marker for the stock. The current valuation combines a negative trailing P/E with a market value well above those of the two selected medical-device peers, giving the report an important role in testing the market view.

Nasdaq close and market setting

Pulse Biosciences ended the October 16, 2026 Nasdaq session at USD 44.43, down 2.54 percent from the prior close. The company remains a healthcare medical-device stock with a scheduled earnings date on November 5, 2026.